Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Multiple myeloma mid-year progress with Dr. Paul Richardson of Dana Farber

  • Broadcast in Health
HealthTree Podcast for MM

HealthTree Podcast for MM


Follow This Show

If you liked this show, you should follow HealthTree Podcast for MM.

Dr. Paul Richardson of the Dana Farber Cancer Institute shares a mid-year myeloma review of ASCO, EHA and upcoming International Myeloma Society findings of the fast-moving research being performed in myeloma. Updates will include the expanding world of bispecific antibodies that include one FDA-approved drug and anticipated approvals for two new bispecific antibodies. He will also discuss exciting results from CAR T cinical trials,  CAR T newcomers, sequencing preferences, BCMA targeted therapies, new therapy targets in myeloma, MRD advances, blood-based testing, clinical trials end points and more. 

Thanks to our episode sponsor, Karyopharm.

Facebook comments

Available when logged-in to Facebook and if Targeting Cookies are enabled